Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Weisman

Internal Medicine Scottsdale, AZ Medical Doctor

NPI 1720038656 CMS profile 259948

9445 E Ironwood Square Dr, Suite 100, Scottsdale, AZ 85258

Open in the dashboard

General payments

$5,133

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Weisman of Scottsdale, AZ is reported in the CMS Open Payments database as having received $5,133 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,065 36
2024 General $679 12
2023 General $602 17
2022 General $696 22
2021 General $753 40
2020 General $824 45
2019 General $513 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Weisman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steven Weisman were reported at $1,065. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steven Weisman Internal Medicine median Middle half National median
2019 $513 $159 $48–$570 $163
2020 $824 $119 $33–$402 $114
2021 $753 $135 $37–$521 $132
2022 $696 $141 $42–$496 $149
2023 $602 $149 $45–$519 $160
2024 $679 $154 $47–$537 $164
2025 $1,065 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,740 29 payments
  2. Amgen Inc. $515 23 payments
  3. Amarin Pharma Inc. $494 44 payments
  4. Lilly USA, LLC $443 14 payments
  5. Novo Nordisk Inc $404 15 payments
  6. Esperion Therapeutics, Inc. $289 11 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $221 8 payments
  8. ITI, Inc. $159 3 payments
  9. Phathom Pharmaceuticals, Inc. $158 2 payments
  10. Allergan Inc. $143 8 payments
  11. Other $569 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,127 187 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $1,226 24 payments
  2. BREZTRI $751 6 payments
  3. AIRSUPRA $560 4 payments
  4. Vascepa $471 42 payments
  5. Ozempic $395 14 payments
  6. MOUNJARO $292 11 payments
  7. NEXLETOL $289 11 payments
  8. Otezla $180 11 payments
  9. AIMOVIG $178 7 payments
  10. CAPLYTA $159 3 payments
  11. Other $1,941 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

4,334

Median for Internal Medicine: 777

Drug cost

$600,455

Median for Internal Medicine: $73,373

Branded share of claims

21.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 115 $155,875
Farxiga Dapagliflozin Propanediol Brand 100 $101,943
Repatha Sureclick Evolocumab Brand 61 $74,949
Vascepa Icosapent Ethyl Brand 58 $47,396
Eliquis Apixaban Brand 26 $36,036
Praluent Pen Alirocumab Brand 42 $35,907
Ozempic Semaglutide Brand 15 $19,765
Icosapent Ethyl Generic 38 $16,964
Rosuvastatin Calcium Generic 819 $12,893
Jardiance Empagliflozin Brand 13 $12,383

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$72,262

Medicare's payments for the services billed

Medicare patients

269

Average age 76

Services billed

837

123 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 49%
Ischemic heart disease 31%
Osteoporosis 25%
Cancer 24%
Diabetes 22%
Heart failure 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $302
$302 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $125
$125 100 —
MOUNJARO
  • Lilly USA, LLC $85
$85 115 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $56
$56 14 —
RYBELSUS
  • Novo Nordisk Inc $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record